No-Flush Niacin (Inositol Hexanicotinate) 500 mg

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar4.8 (581 ratings)
Format:Capsule Quantity: 100 Capsule(s) · 100 servings
Goals

Product analysis

61 out of 100

No-Flush Niacin (Inositol Hexanicotinate) 500 mg offers a low-cost niacin-focused supplement. Its no-flush preparation cannot be assumed to share the blood-lipid effects of nicotinic acid, limiting its appeal for that purpose.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality20

The no-flush description identifies a different preparation from nicotinic acid. Incomplete separate form details limit a firm comparison of the niacin and inositol contributions.

Ingredient Transparency63

Niacin and inositol amounts are stated. Their separate form entries are incomplete, so the compound name should not be used to infer nutrient yield.

Value For Money100

The labeled niacin serving is inexpensive. That price advantage does not establish equivalence to other niacin preparations.

Customer Satisfaction80

Ratings indicate very high satisfaction. The feedback base is useful but smaller than for heavily reviewed supplements.

Product Focus67

The formula stays focused on niacin-related use. Its cardiovascular relevance is limited because the no-flush preparation does not establish the effects associated with nicotinic acid.

Format
Capsule
Container
100 Capsule(s)
Per serving
$0.18
Customer rating
4.8 · 581 ratings
Report analysis

Goals

Cardiovascular Support
Impact
High effect
B- Ingredient FitD PathwaysB- EvidenceA+ Formulation Logic
Niacin · 400 mg
Study evidence
Niacin Supportive 136 studies
Heart Health
Impact
Moderate effect
B- Ingredient FitF PathwaysC EvidenceA+ Formulation Logic
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Niacin
400 mg 73
Inositol
100 mg
Gluten Free Adults 18–50 Vegan Kosher Dairy Free Sugar Free Vegetarian
Report overview
Niacin · 400 mg OverallScore73
C- Active Ingredient Quality & BioavailabilityB Dose, Safety & Label TransparencyA+ Value
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin